Biomarkers
A liquid biopsy for detecting circulating mesothelial precursor cells: A new biomarker for diagnosis and prognosis in mesothelioma
EBioMedicine 2020 October 9 [Link] Bill T V Duong, Licun Wu, Brenda J Green, Fatemeh Bavaghar-Zaeimi, Zongjie Wang, Mahmoud Labib, Yuxiao Zhou, Fernando J P Cantu, Thurgaa Jeganathan, Sandra Popescu, Jennifer Pantea, Marc de Perrot, Shana O Kelley Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive cancer related to asbestos exposure. Early diagnosis is…
Read MoreTargeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma
Pharmaceuticals 2020 October 2 [Link] Puey-Ling Chia, Sagun Parakh, Ming-Sound Tsao, Nhu-An Pham, Hui K Gan, Diana Cao, Ingrid J G Burvenich, Angela Rigopoulos, Edward B Reilly, Thomas John, Andrew M Scott Abstract Epidermal growth factor receptor (EGFR) is highly overexpressed in malignant mesothelioma (MM). MAb806 is a novel anti-EGFR antibody that selectively targets a…
Read MoreImmunotherapy for mesothelioma: rationale and new approaches
Clinical Advances for Hematology and Oncology 2020 September [Link] Joshua E Reuss, Patrick M Forde Abstract Therapeutic advancement for mesothelioma has been stagnant, with minimal treatment innovation in the past decade. Recently, however, immune checkpoint blockade (ICB) targeting the programmed death 1 and cytotoxic T-lymphocyte-associated antigen 4 pathways has revolutionized the treatment of multiple malignancies…
Read MoreAssociation of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
The Lancet Oncology 2020 October [Link] Aurélien Marabelle, Marwan Fakih, Juanita Lopez, Manisha Shah, Ronnie Shapira-Frommer, Kazuhiko Nakagawa, Hyun Cheol Chung, Hedy L Kindler, Jose A Lopez-Martin, Wilson H Miller Jr, Antoine Italiano, Steven Kao, Sarina A Piha-Paul, Jean-Pierre Delord, Robert R McWilliams, David A Fabrizio, Deepti Aurora-Garg, Lei Xu, Fan Jin, Kevin Norwood, Yung-Jue…
Read MoreVerification of a Blood-Based Targeted Proteomics Signature for Malignant Pleural Mesothelioma
Cancer Epidemiology, Biomarkers, and Prevention 2020 July 30 [Link] Ferdinando Cerciello, Meena Choi, Sara L Sinicropi-Yao, Katie Lomeo, Joseph M Amann, Emanuela Felley-Bosco, Rolf A Stahel, Bruce W S Robinson, Jenette Creaney, Harvey I Pass, Olga Vitek, David P Carbone Abstract Background: We have verified a mass spectrometry (MS)-based targeted proteomics signature for the detection…
Read MoreNew vistas in malignant mesothelioma: MicroRNA architecture and NRF2/MAPK signal transduction
Life Sciences 2020 July 22 [Link] Manav Gandhi, Sujit Nair Abstract Malignant mesothelioma (MM) is a cancer of the mesothelial lining of the pleura, peritoneum, pericardium and testes. The most common form is asbestos-linked MM that is etiologically linked to repeated asbestos exposure with a long latency period, although non-asbestos MM has also been reported.…
Read MoreMesothelioma Biomarkers: A Review Highlighting Contributions from the Early Detection Research Network
Cancer Epidemiology, Biomarkers, and Prevention 2020 July 22 [Link] Harvey I Pass, Marjan Alimi, Michele Carbone, Haining Yang, Chandra M Goparaju Abstract Background: Malignant Pleural Mesothelioma (MPM) is an asbestos related neoplasm which can only be treated successfully when correctly diagnosed and treated in early stages. The asbestos exposed population serves as a high risk…
Read MoreVerification of a blood based targeted proteomics signature for malignant pleural mesothelioma
Cancer Epidemiol Biomarkers, July 30, 2020 (Epub ahead of print) [Link] Ferdinando Cerciello, et.al. Abstract Background: We have verified a mass spectrometry (MS) based targeted proteomics signature for the detection of malignant pleural mesothelioma (MPM) from the blood. Methods: A seven-peptide biomarker MPM signature by targeted proteomics in serum was identified in a previous independent…
Read MoreTreatment response monitoring in patients with advanced malignancies using cell-free SHOX2 and SEPT9 DNA methylation in blood: An observational prospective study.
The Journal of Molecular Diagnostics 2020 April 30 [Link] de Vos L, Jung M, Koerber RM, Bawden EG, Holderried TAW, Dietrich J, Bootz F, Brossart P, Kristiansen G, Dietrich D Abstract Patients with incurable cancer usually receive palliative treatment with significant toxicity and limited efficacy. Methylation analysis of circulating cell-free DNA in blood from cancer…
Read MorePutative Biomarkers for Malignant Pleural Mesothelioma Suggested by Proteomic Analysis of Cell Secretome.
Cancer Genomics & Proteomics 2020 May-June [Link] Lacerenza S, Ciregia F, Giusti L, Bonotti A, Greco V, Giannaccini G, D’Antongiovanni V, Fallahi P, Pieroni L, Cristaudo A, Lucacchini A, Mazzoni MR, Foddis R Abstract BACKGROUND:Malignant pleural mesothelioma (MPM) a rare neoplasm linked to asbestos exposure is characterized by a poor prognosis. Soluble mesothelin is currently…
Read More